Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients. Takeda's Adzynma becomes ...
WASHINGTON — The Food and Drug Administration has approved the first drug treatment for pediatric patients 12 and older with a rare blood disorder. The treatment for acquired thrombotic ...
A Takeda Pharmaceutical drug is now the first FDA-approved therapy for a rare, inherited enzyme deficiency that leads to blood clotting problems and a cascade of complications, some of them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results